Our Team - Biognosys
Contact us Helpdesk

Our Team


Oliver Rinner, PhD

Founder, CEO, Board Director
Oliver was a co-founder of Biognosys in 2008 and is leading the company as CEO, starting as a spin-off from ETH Zurich to a market-leading inventor and provider of proteomics technology that Biognosys is today.

Karel Novy, PhD

Chief Operating Officer
Karel joined Biognosys in 2016 and held positions of increasing responsibility in Business Development and Scientific Operations. As COO Karel is responsible for the Operations department focusing on contract research projects.

Kristina Beeler, PhD

Chief Business Officer
Kristina leads the business activities of the services offering of Biognosys. Her team enables Biognosys’ global partners to utilize proteomics to address the key challenges in their research.

Lidia Novak, CFA

Chief Financial Officer
Lidia joined Biognosys as CFO in 2018 and is in charge of finance functions including assessment of strategic initiatives and relations with existing and potential investors.

Lukas Reiter, PhD

Chief Technology Officer
Lukas joined Biognosys among the first employees in 2010. As CTO, he oversees research as well as product and workflow development. He has authored key publications in computational proteomics and is a co-inventor of the SWATH technology.

Commercial Heads

Sira Echevarría Zomeño, PhD

Head of Business Development - Products
Sira is responsible for Biognosys’ products business development and sales, and our customer success. Her team is committed to enabling researchers and mass spectrometry users to apply state-of-the-art proteomics technologies to their research.

Yves Serroen

Head of Marketing
Yves leads the marketing team at Biognosys, which is focused on raising awareness and adoption of Biognosys’ next-generation proteomics platform in both the products and services markets.

Sebastian Schegk, PhD

Head of Data Business
Large-Scale Proteomics will transform proteome data into an important data asset complementary to genomic data and RWE. As Head of Data Business, Sebastian leads that field for Biognosys in collaboration with partners and clients.

Ben Gonzales, MBA

Head of Sales, North America
Ben Gonzales comes with a history of life science and proteomics commercial development with a track record of successfully growing products and services business. As Head of Sales, North America, Ben will be responsible for growing the business and the team in the North American market, in support of Biognosys’ contract research offerings.

Board of directors

Patrick Vink, MD

Patrick Vink joined the Biognosys board of directors as Chairman in June 2020. He is an advisor to life science companies and a non– executive Chairman and Board member of several publicly listed and privately held companies.

Oliver Rinner, PhD

In addition to his position as CEO, Oliver also serves as Director on the Biognosys board.

Dean Haworth

Dean Haworth is Investment Manager Venture Capital at PM Equity Partner. He is a seasoned investment professional with 13 years experience supporting and leading Venture Capital and Private Equity investments on behalf of family offices and multinational corporations.

Michael Lee, PhD

Michael Lee has been Managing Director at Syngenta Ventures since 2013. Prior to this, he spent several years at Unilever’s corporate venturing group based in the US and UK investing in early-stage companies. Before this, he worked at Unilever’s R&D center in the Netherlands.

Winfried Mayer, PhD

Winfried Mayer was the former Head of Manufacturing at Roche Pharmaceuticals and advisor to Chugai Pharmaceutical, Japan, and brings over 30 years of pharmaceutical industry experience.

Manuel Peitsch, PhD

Manuel Peitsch is Chief Science Officer at Philip Morris International and holds board positions at several life sciences companies and organizations, including Biognosys, the Swiss Institute of Bioinformatics, and [BC]2, Basel Computational Biology Conference.

Christian Wolfrum, PhD

Christian Wolfrum is Head of New Business Development and Planning at Siemens Healthineers AG. Additionally, he holds board positions at Biognosys and Open Source Imaging Consortium (OSIC), a cooperative effort between academia, industry, and philanthropy to enable rapid advances in the fight against Idiopathic Pulmonary Fibrosis (IPF) and other progressive interstitial lung diseases (ILDs).

Scientific Advisory Board

Prof. Dr. Ruedi Aebersold

Ruedi, a co-founder of Biognosys, is one of the pioneers in the field of proteomics. He serves on the Scientific Advisory Committees of numerous academic and private-sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics.

Prof. Dr. Johan Malmstroem

Johan, Associate Professor at the University of Lund, Sweden, obtained his PhD in a collaboration between Lund University and AstraZeneca R&D Lund. In 2001 he co-founded Ludesi AB. In 2003, Johan joined the Institute for Systems Biology in Seattle, and in 2004, he transferred to the Aebersold lab at the ETH Zurich, where he was involved in the development and application of targeted proteomics technologies and co-founded Biognosys.

Prof. Dr. Paola Picotti

Paola obtained her PhD from the University of Padova. In 2006, she joined Prof. Ruedi Aebersold’s group at ETH Zurich, where her research received the ETH Latsis Prize 2011. At the beginning of 2011, she started her own research group and in 2017 she was appointed professor at the Institute of Molecular Systems Biology at ETH Zurich.

Our expert team is glad to answer any questions you have.